Cambridge, UK, 1st February 2018 / Sciad Newswire / Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce that Dr Kevin Doyle has been appointed Head of Chemistry with immediate effect. His appointment strengthens the expanding team of international scientists at its research facilities on Chesterford Research Park, based in Cambridge, UK, which has grown by more than 50% in the past 18 months.
‘I am delighted to join the team at Domainex,’ said Dr Doyle. ‘Domainex is clearly a rapidly-growing CRO and has been ‘one to watch’ for some time now. The opportunity to be a part of it, and to help shape the future of its medicinal chemistry was one that I could not miss. I am looking forward to working alongside the talented scientists there and to meeting and supporting the impressive list of clients from all around the world.’
Kevin Doyle is a medicinal chemist with more than 20 years’ experience in the pharmaceutical industry. He joins Domainex from Charles River Laboratories where he led numerous integrated drug discovery projects with international pharmaceutical and biotech companies, as well as with patient foundations. In previous roles, he worked at BASF and OSI Pharmaceuticals.
‘We are delighted to welcome Kevin to Domainex,’ commented Dr Tom Mander, COO of the company. ‘His wealth of experience within the contract drug discovery research environment will be invaluable in helping Domainex to strengthen our integrated drug discovery platform further. Kevin will play a strategic role in attracting more pharmaceutical and biotechnology companies to Domainex, developing innovative new services and helping to extend our reputation for delivering innovative new medicinal therapies for our clients.’
Ends
For more information contact:
Domainex
Dr Tom Mander
T: +44 (0)7584 578024
E: tom.mander@domainex.co.uk
Media Relations – Sciad Communications
Deborah Cockerill / Emma Pickup
T: +44(0)20 7470 8801
E: domainex@sciad.com
Notes to Editors
About Domainex
Established in 2001 as a spin-out from University College London, Birkbeck College, and the Institute of Cancer Research, Domainex Ltd. is a Cambridge-based, privately-owned company that provides integrated medicines research services to global pharmaceutical, biotechnology and academic partners. Its services cover a wide span of the drug research value chain, from disease target selection to pre-clinical candidate nomination. Domainex's services include recombinant protein expression and use of its proprietary technology platform, Combinatorial Domain Hunting to identify soluble protein fragments for structural biology and assay development. Hit finding activities encompass assay development and screening utilising its BioassayBuilder, FragmentBuilder and LeadBuilder platforms. The core of the service offering is undertaking multi-parameter medicinal chemistry optimisation of hits and leads with its ‘every compound counts’ approach, which can save up to 30% on the average industry time from target to candidate.
For more information please visit www.domainex.co.uk